Your browser doesn't support javascript.
loading
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova, Beata; Kmieciak, Maciej; Perkins, E Brent; Bose, Prithviraj; Baz, Rachid C; Roodman, G David; Stuart, Robert K; Ramakrishnan, Viswanathan; Wan, Wen; Peer, Cody J; Dawson, Jana; Kang, Loveleen; Honeycutt, Connie; Tombes, Mary Beth; Shrader, Ellen; Weir-Wiggins, Caryn; Wellons, Martha; Sankala, Heidi; Hogan, Kevin T; Colevas, A Dimitrios; Doyle, L Austin; Figg, William D; Coppola, Domenico; Roberts, John D; Sullivan, Daniel; Grant, Steven.
Afiliación
  • Holkova B; Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia. bholkova@mcvh-vcu.edu.
  • Kmieciak M; Massey Cancer Center and.
  • Perkins EB; Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Bose P; Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Baz RC; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Roodman GD; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Stuart RK; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Ramakrishnan V; Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
  • Wan W; Department of Biostatistics, Virginia Commonwealth University, Richmond, Virginia.
  • Peer CJ; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Dawson J; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Kang L; James A. Haley Veterans' Hospital, Tampa, Florida.
  • Honeycutt C; Massey Cancer Center and.
  • Tombes MB; Massey Cancer Center and.
  • Shrader E; Massey Cancer Center and.
  • Weir-Wiggins C; Massey Cancer Center and.
  • Wellons M; Massey Cancer Center and.
  • Sankala H; Massey Cancer Center and.
  • Hogan KT; Massey Cancer Center and.
  • Colevas AD; Cancer Therapy Evaluation Program, NCI, NIH, Bethesda, Maryland. Departments of.
  • Doyle LA; Cancer Therapy Evaluation Program, NCI, NIH, Bethesda, Maryland. Departments of.
  • Figg WD; Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Coppola D; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Roberts JD; Massey Cancer Center and Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia.
  • Sullivan D; Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
  • Grant S; Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and Massey Cancer Center and.
Clin Cancer Res ; 20(22): 5652-62, 2014 Nov 15.
Article en En | MEDLINE | ID: mdl-25248382

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Protocolos de Quimioterapia Combinada Antineoplásica / Trastornos Linfoproliferativos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Protocolos de Quimioterapia Combinada Antineoplásica / Trastornos Linfoproliferativos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2014 Tipo del documento: Article Pais de publicación: Estados Unidos